Doc Hudson

Error creating thumbnail:

Error creating thumbnail:

Error creating thumbnail:

Cyclin-dependent kinase 4 (CDK4) is an enzyme that in humans is encoded by the CDK4 gene. It plays a crucial role in the cell cycle, particularly in the transition from the G1 phase to the S phase, making it a key regulator of cell division and cell growth. CDK4, along with its close relative CDK6, forms a complex with D-type cyclins, which are necessary for the progression through the G1 phase of the cell cycle. This kinase is also involved in the pathogenesis of various types of cancer, as its deregulation can lead to uncontrolled cell proliferation.

Function

CDK4 is a member of the Cyclin-dependent kinase family, which are serine/threonine kinases. These kinases are critical for the control of the cell cycle. CDK4 specifically is activated by binding to D-type cyclins, which are expressed in response to mitogenic signals. Once activated, the CDK4/cyclin D complex phosphorylates and inactivates the Rb protein, leading to the release of E2F transcription factors. The activation of E2F targets genes that are necessary for DNA synthesis, thus promoting the G1/S transition in the cell cycle.

Clinical Significance

The dysregulation of CDK4 has been implicated in the development of several types of cancer, including melanoma, breast cancer, and glioblastoma. In some cases, mutations in the CDK4 gene lead to an increase in kinase activity, which can contribute to oncogenesis by promoting uncontrolled cell proliferation. Additionally, CDK4 has been a target for cancer therapy, with several CDK4/6 inhibitors being developed and approved for the treatment of certain types of breast cancer. These inhibitors work by preventing the phosphorylation of Rb, thereby blocking the cell cycle progression at the G1 phase.

CDK4 Inhibitors

CDK4 inhibitors are a class of drugs that specifically target CDK4/6 kinase activity. These inhibitors have shown promise in treating cancers that are driven by the overactivity of CDK4, such as certain hormone receptor-positive breast cancers. Palbociclib, ribociclib, and abemaciclib are examples of CDK4/6 inhibitors that have been approved for clinical use. These drugs are typically used in combination with hormone therapy, enhancing the effectiveness of treatment by synergistically inhibiting cancer cell proliferation.

Doc Hudson

The reference to "Doc Hudson" in the context of CDK4 does not correspond to any known scientific terminology or entity related to the gene or its associated pathways. Doc Hudson may refer to a character from popular culture, unrelated to the scientific discussion of Cyclin-dependent kinase 4.